Related references
Note: Only part of the references are listed.The oncoprotein LMO2 is expressed in normal germinal-center B cells and in human B-cell lymphomas
Yasodha Natkunam et al.
BLOOD (2007)
Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma
Thomas M. Habermann et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study
Jane N. Winter et al.
BLOOD (2006)
CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma:: a randomised controlled trial by the MabThera International Trial (MInT) Group
Michael Pfreundschuh et al.
LANCET ONCOLOGY (2006)
Prognostic biomarkers in diffuse large B-cell lymphoma
IS Lossos et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
The role of LMO2 in development and in T cell leukemia after chromosomal translocation or retroviral insertion
CH Nam et al.
MOLECULAR THERAPY (2006)
Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia
LH Sehn et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Expression of the human germinal center-associated lymphoma (HGAL) protein, a new marker of germinal center B-cell derivation
Y Natkunam et al.
BLOOD (2005)
Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes
IS Lossos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Activation of the T-cell oncogene LMO2 after gene therapy for X-linked severe combined immunodeficiency
MP McCormack et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Building an outcome predictor model for diffuse large B-cell lymphoma
AI Sáez et al.
AMERICAN JOURNAL OF PATHOLOGY (2004)
Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray
CP Hans et al.
BLOOD (2004)
A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma
G Wright et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL)
N Mounier et al.
BLOOD (2003)
Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma
L Colomo et al.
BLOOD (2003)
The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma
A Rosenwald et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma
SL Barrans et al.
BLOOD (2002)
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
B Coiffier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning
MA Shipp et al.
NATURE MEDICINE (2002)
Germinal center reaction
LJ McHeyzer-Williams et al.
CURRENT OPINION IN HEMATOLOGY (2001)
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
AA Alizadeh et al.
NATURE (2000)
The oncogenic LIM-only transcription factor Lmo2 regulates angiogenesis but not vasculogenesis in mice
Y Yamada et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)